caa a22 4500 605490910 CHVBK 20210128100507.0 cr unu---uuuuu 210128e20150601xx s 000 0 eng 10.1007/s10147-014-0737-8 doi (NATIONALLICENCE)springer-10.1007/s10147-014-0737-8 Late toxicity of proton beam therapy for patients with the nasal cavity, para-nasal sinuses, or involving the skull base malignancy: importance of long-term follow-up [Elektronische Daten] [Sadamoto Zenda, Mitsuhiko Kawashima, Satoko Arahira, Ryosuke Kohno, Teiji Nishio, Makoto Tahara, Ryuichi Hayashi, Tetsuo Akimoto] Background: Although several reports have shown that proton beam therapy (PBT) offers promise for patients with skull base cancer, little is known about the frequency of late toxicity in clinical practice when PBT is used for these patients. Here, we conducted a retrospective analysis to clarify the late toxicity profile of PBT in patients with malignancies of the nasal cavity, para-nasal sinuses, or involving the skull base. Methods: Entry to this retrospective study was restricted to patients with (1) malignant tumors of the nasal cavity, para-nasal sinuses, or involving the skull base; (2) definitive or postoperative PBT (>50GyE) from January 1999 through December 2008; and (3) more than 1year of follow-up. Late toxicities were graded according to the common terminology criteria for adverse events v4.0 (CTCAE v4.0). Results: From January 1999 through December 2008, 90 patients satisfied all criteria. Median observation period was 57.5months (range, 12.4-162.7 months), median time to onset of grade 2 or greater late toxicity except cataract was 39.2months (range, 2.7-99.8 months), and 3 patients had toxicities that occurred more than 5years after PBT. Grade 3 late toxicities occurred in 17 patients (19%), with 19 events, and grade 4 late toxicities in 6 patients (7%), with 6 events (encephalomyelitis infection 2, optic nerve disorder 4). Conclusions: In conclusion, the late toxicity profile of PBT in patients with malignancy involving the nasal cavity, para-nasal sinuses, or skull base malignancy was partly clarified. Because late toxicity can still occur at 5years after treatment, long-term follow-up is necessary. Japan Society of Clinical Oncology, 2014 Proton beam therapy nationallicence Late toxicity nationallicence Follow-up nationallicence Head and neck cancer nationallicence Zenda Sadamoto Division of Radiation Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, 277-8577, Kashiwa, Chiba, Japan aut Kawashima Mitsuhiko Division of Radiation Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, 277-8577, Kashiwa, Chiba, Japan aut Arahira Satoko Division of Radiation Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, 277-8577, Kashiwa, Chiba, Japan aut Kohno Ryosuke Division of Radiation Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, 277-8577, Kashiwa, Chiba, Japan aut Nishio Teiji Division of Radiation Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, 277-8577, Kashiwa, Chiba, Japan aut Tahara Makoto Division of Head and Neck Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, 277-8577, Kashiwa, Chiba, Japan aut Hayashi Ryuichi Division of Head and Neck Surgery, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, 277-8577, Kashiwa, Chiba, Japan aut Akimoto Tetsuo Division of Radiation Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, 277-8577, Kashiwa, Chiba, Japan aut International Journal of Clinical Oncology Springer Japan 20/3(2015-06-01), 447-454 1341-9625 20:3<447 2015 20 10147 https://doi.org/10.1007/s10147-014-0737-8 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-014-0737-8 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Zenda Sadamoto Division of Radiation Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, 277-8577, Kashiwa, Chiba, Japan aut NATIONALLICENCE 700 1- Kawashima Mitsuhiko Division of Radiation Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, 277-8577, Kashiwa, Chiba, Japan aut NATIONALLICENCE 700 1- Arahira Satoko Division of Radiation Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, 277-8577, Kashiwa, Chiba, Japan aut NATIONALLICENCE 700 1- Kohno Ryosuke Division of Radiation Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, 277-8577, Kashiwa, Chiba, Japan aut NATIONALLICENCE 700 1- Nishio Teiji Division of Radiation Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, 277-8577, Kashiwa, Chiba, Japan aut NATIONALLICENCE 700 1- Tahara Makoto Division of Head and Neck Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, 277-8577, Kashiwa, Chiba, Japan aut NATIONALLICENCE 700 1- Hayashi Ryuichi Division of Head and Neck Surgery, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, 277-8577, Kashiwa, Chiba, Japan aut NATIONALLICENCE 700 1- Akimoto Tetsuo Division of Radiation Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, 277-8577, Kashiwa, Chiba, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/3(2015-06-01), 447-454 1341-9625 20:3<447 2015 20 10147